The current article adds that the Phase 3 ALOFT-IPF trial tested admilparant at 60 mg and 120 mg doses administered twice daily for at least 52 weeks versus placebo. This dosing detail was not previously specified in the topline results announcement.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
